BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32271355)

  • 1. Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.
    Asbell PA; Sanfilippo CM; Sahm DF; DeCory HH
    JAMA Ophthalmol; 2020 May; 138(5):439-450. PubMed ID: 32271355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
    Asbell PA; Sanfilippo CM; Pillar CM; DeCory HH; Sahm DF; Morris TW
    JAMA Ophthalmol; 2015 Dec; 133(12):1445-54. PubMed ID: 26502312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study.
    Asbell PA; DeCory HH
    PLoS One; 2018; 13(10):e0205814. PubMed ID: 30335799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.
    Alter SJ; Sanfilippo CM; Asbell PA; DeCory HH
    Pediatr Infect Dis J; 2019 Feb; 38(2):138-145. PubMed ID: 30281547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
    Sanfilippo CM; Morrissey I; Janes R; Morris TW
    Curr Eye Res; 2016 May; 41(5):581-9. PubMed ID: 26200173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study.
    Haas W; Pillar CM; Torres M; Morris TW; Sahm DF
    Am J Ophthalmol; 2011 Oct; 152(4):567-574.e3. PubMed ID: 21652021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Antibiotic Resistance among Bacteria from the Cornea in the Antibiotic Resistance Monitoring in Ocular MicRoorganisms Surveillance Study.
    Thomas RK; Melton R; Vollmer PM; Asbell PA
    Optom Vis Sci; 2021 Sep; 98(9):1113-1121. PubMed ID: 34510155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).
    Thomas RK; Melton R; Asbell PA
    Clin Optom (Auckl); 2019; 11():15-26. PubMed ID: 30881168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study.
    Asbell PA; Pandit RT; Sanfilippo CM
    Ophthalmol Ther; 2018 Dec; 7(2):417-429. PubMed ID: 30094698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humour in the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) Surveillance Study: 2009-2020 update.
    Asbell PA; Sanfilippo CM; Mah FS
    J Glob Antimicrob Resist; 2022 Jun; 29():236-240. PubMed ID: 35339737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance of bacterial pathogens isolated from the conjunctiva in the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study (2009-2021).
    Asbell PA; Sanfilippo CM; DeCory HH
    Diagn Microbiol Infect Dis; 2024 Jan; 108(1):116069. PubMed ID: 37918187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.
    Asbell PA; Colby KA; Deng S; McDonnell P; Meisler DM; Raizman MB; Sheppard JD; Sahm DF
    Am J Ophthalmol; 2008 Jun; 145(6):951-958. PubMed ID: 18374299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Epidemiology and Antibiotic Resistance of Ocular Infections.
    Miller D
    Middle East Afr J Ophthalmol; 2017; 24(1):30-42. PubMed ID: 28546690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States.
    Bispo PJM; Sahm DF; Asbell PA
    Ophthalmol Ther; 2022 Apr; 11(2):503-520. PubMed ID: 35113406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular pathogens and antibiotic resistance in microbial keratitis over three years in Harbin, Northeast China.
    Xu S; Guo D; Liu X; Jin X; Shi Y; Wang Y; Zhang N; Zhang H
    Acta Ophthalmol; 2021 Dec; 99(8):909-915. PubMed ID: 33565253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.
    McDonald M; Blondeau JM
    J Cataract Refract Surg; 2010 Sep; 36(9):1588-98. PubMed ID: 20692574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.
    Asbell PA; Sahm DF; Shaw M; Draghi DC; Brown NP
    J Cataract Refract Surg; 2008 May; 34(5):814-8. PubMed ID: 18471638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial resistance trends in bacterial keratitis over 5 years in Sydney, Australia.
    Cabrera-Aguas M; Khoo P; George CRR; Lahra MM; Watson SL
    Clin Exp Ophthalmol; 2020 Mar; 48(2):183-191. PubMed ID: 31671232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
    Miller D; Chang JS; Flynn HW; Alfonso EC
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.